The Bioregulator Family: One Peptide Per Organ, and the Idea Behind It

The Idea in One Paragraph

Every organ in the body produces its own short peptides. The proposal behind the bioregulator family is that these peptides act as maintenance instructions for the tissue that makes them — and that production falls away with age and stress. Supply the peptide a tissue has stopped making enough of, the argument runs, and you help that tissue return to its own normal pattern of activity.

That single idea produced around twenty compounds. Each is tiny — two to four amino acids — and each is aimed at one tissue. Thymalin at the thymus. Cortexin at the brain. Livagen at the liver. Cardiogen at the heart. The list reads almost like an anatomical index, because that is exactly how it was built.

The whole family, in plain language: imagine every organ in your body keeping a short instruction card that says how it is meant to run — when to repair, when to rest, what to produce. When you are young the cards are crisp and everyone follows them. With age the ink fades. The bioregulator idea is to hand a tissue a fresh copy of its own card. Not a new instruction, not a stimulant, not an override — the same instruction it was already following, printed clearly again. And crucially, the liver’s card is no use to the thymus, which is why there is a separate peptide for each organ rather than one that does everything.

Where They Came From

The programme began in 1973 under Professor Vladimir Khavinson (1946–2024), a military physician working on a specific Soviet problem: personnel in extreme conditions — submariners, missile-crew, cosmonauts — were showing signs of premature ageing, immune decline and tissue breakdown. The brief was to find something protective that would not damage the liver or kidneys of people already under severe physiological stress.

His group took a different route from conventional pharmacology. Instead of designing a drug to force a response, they extracted short peptides from healthy animal organ tissue and asked whether returning those peptides to aged or damaged tissue restored normal function. The early compounds were extracts — Thymalin from thymus, Epithalamin from pineal gland, Cortexin from brain. Later work identified the active sequences and synthesised them directly, which is where Epitalon, Pinealon, Vilon and the rest come from.

Over four decades the institute published more than 775 papers and held 196 patents. Khavinson was nominated for the Nobel Prize in Medicine in 1996 for the proposal that short peptides act as gene switches. He remained director of the St. Petersburg Institute of Bioregulation and Gerontology until his death in 2024.

Extracts and Synthetics: Not the Same Thing

This distinction causes more confusion than anything else in the field, and it is worth getting straight before looking at any individual compound.

The first generation were natural extracts — purified peptide fractions taken from animal organs. Thymalin, Epithalamin, Cortexin and Retinalamin belong here. They are mixtures, not single molecules, and they are the compounds with the longest clinical history in Russia.

The second generation are synthesised single peptides with a defined sequence. Epitalon (Ala-Glu-Asp-Gly) is the synthetic counterpart of Epithalamin. Vilon is Lys-Glu. Livagen is Lys-Glu-Asp-Ala. Cortagen is Ala-Glu-Asp-Pro. Vesugen is Ala-Glu-Asp-Leu. These are exact molecules that can be made to a specification and tested by HPLC — which is why they, rather than the extracts, are what a research supplier can actually verify.

Why the difference matters, in plain language: an extract is a stock made from a whole chicken; a synthetic peptide is one named spice. The stock may well contain the useful ingredient, but you cannot say precisely what is in it, and no two batches are identical. The spice you can weigh, test and reproduce exactly. When you see a purity figure of ≥99% on a bioregulator, that figure only means something for the synthesised kind — you cannot meaningfully assign a purity percentage to a mixture.

The Family, Organ by Organ

Roughly twenty compounds make up the family. These are the ones that appear most often in the literature and in research supply:

The naming follows a loose logic once you see it — Livagen from liver, Cardiogen from cardiac, Bronchogen from bronchi, Cartalax from cartilage. Pinealon is the exception that catches people out: despite the name, it is studied for brain and central nervous tissue rather than the pineal gland. Epitalon is the pineal one.

How They Are Proposed to Work

Most signalling peptides act at the cell surface: they bind a receptor on the outside of a cell, which triggers a response inside. Bioregulators are proposed to act deeper — passing into the cell nucleus and influencing which genes a tissue is actively reading.

The size argument is central. At two to four amino acids these molecules are extremely small, small enough that the literature proposes they can cross both the cell membrane and the nuclear membrane and interact with DNA and its packaging proteins. The proposed effect is not to alter the genetic code but to change which parts of it are being read — turning the volume up on some instructions and down on others.

Gene expression, in plain language: every cell carries the same complete cookbook. A liver cell and a brain cell hold identical recipes; what differs is which pages each one has open. Gene expression is which pages are open. The bioregulator proposal is not that these peptides rewrite any recipe — the cookbook is untouched — but that they help a tissue turn back to the pages it is supposed to be using, in a tissue where the wrong pages have gradually been left open.

The word proposed is doing real work in this section. This is the mechanism the research programme advances, and it is coherent and specific. It is not, on the current published record, settled fact.

The Evidence, Honestly

This is the part most write-ups skip, and it is the part that matters most.

What is genuinely well documented. The programme is enormous and real: four decades, 775-plus papers, six peptide pharmaceuticals introduced into clinical practice in Russia and the CIS. Thymalin has been in clinical use there since the 1980s. Animal studies from the institute report meaningful lifespan and healthspan effects across several species. Epitalon’s telomerase result has been independently replicated in human cell culture.

What is not. The great majority of this work originates from the institute that developed the compounds, and independent Western replication remains limited. Much of the literature is Russian-language and was produced under a regulatory framework different from FDA or EMA drug approval. For most individual bioregulators outside Epitalon and Thymalin, the published evidence is thin — often a handful of papers, largely preclinical, frequently from the same group.

None of the family is approved by the TGA, FDA or EMA. The Russian approvals that do exist apply to specific pharmaceutical products in that country, not to research-grade compounds elsewhere.

How to hold both facts at once: a large, coherent, decades-long research programme with a specific proposed mechanism — and a shortage of independent verification. Neither "proven anti-ageing breakthrough" nor "pseudoscience" is an accurate summary. It is an open scientific question with more work behind it than most research peptides and less outside confirmation than its enthusiasts suggest. That is genuinely where it sits, and anyone telling you otherwise in either direction is overselling.

Frequently Asked Questions

Published References

1. Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed
2. Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
3. Khavinson VKh, Bondarev IE, Butyugov AA. “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.” Bulletin of experimental biology and medicine, 2003. PubMed
4. Khavinson VK, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Karger AG, Basel, 2005. Source
5. Fedoreyeva LI, Kireev II, Khavinson VKh, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry. Biokhimiia, 2011. PubMed
6. Araj SK, Brzezik J, Mądra-Gackowska K, et al. “Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties.” International journal of molecular sciences, 2025. PubMed